

RYSTIGGO (ROZANOLIXIZUMAB-NOLI) ORDER SET

P: 877.365.5566 | **F:** 855.889.2946

PATIENT IN	FORMATION:	Fax completed form,	insurance information	n, and clinical documen	tation to 855.889.2946	
Patient Name: _			DOB:	Phone: _		
Patient Status:	☐ New to Therapy	☐ Continuing Thera	py Next Treat	ment Date:		
MEDICAL IN	FORMATION					
] Myasthenia Grav] Myasthenia Grav] Other:	vis w/acute exac	erbation (ICD)-10: G70.01)	·	
gMG Classific	cation: 🗆 🗀	□IV				
Patient Weigh	t: lbs. (rec	juired) Allergies:				
THERAPY OF	RDER					
Rystiggo	voighing loss than E	Oka (110 lba) Dva	tiana 120ma si	ub O wooldhy for G	wooks	
☐ Patients w	eighing less than 5	ouky (110 lbs.) Rys	tiggo 420mg st	ibQ weekly for 6	weeks	
☐ Patients w	veighing 50kg to <1	00kg (220 lbs.) R	ystiggo 560mg	subQ weekly for	6 weeks	
☐ Patients w	veighing ≥100kg (22	20 lbs.) Rystiggo 8	340mg subQ we	eekly for 6 weeks	5	
	repeated based on Repeat for			63 days from start of	f previous cycle	
Other orders:					_	
	to be drawn by: [nfusion 🗌 Other:		
	ection Ana-kit (adult): er protocol EpiPen 0.3r	ng IM (2-pack)				
PROVIDER II	NFORMATION					
agent in dealing with med	tilizing our services, you are autho ical and prescription insurance con Phone: ragon selecting site (nanies and to select the prefer	ad site of care for the nation	+		
PREFERRED LOCATION						
				OKSE O		
City:	State	:	View our location	ns here:		



COMPREHENSIVE SUPPORT FOR RYSTIGGO THERAPY

Patient Name: DOB: REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL
☐ Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)
\square Include patient demographic information and insurance information
☐ Include patient's current medication list
☐ Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
☐ Has the patient had a documented contraindication/intolerance or failed trial of conventional therapy (i.e., pyridostigmine, immunosuppressants, corticosteroids, or acetylcholinesterase inhibitors)? ☐ Yes ☐ No If yes, which drug(s)?
 ☐ Has the patient required 2 or more courses of plasmapheresis/plasma exchanges and/or intravenous immune globulin for at least 12 months without symptom control? ☐ Yes ☐ No
Myasthenia Gravis Activities of Daily Living (MG-ADL) Score:
 □ Does patient have a history of abnormal neuromuscular transmission test demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation? □ Yes □ No
\square Does the patient have a history of positive anticholinesterase test? \square Yes \square No
☐ Include labs and/or test results to support diagnosis
AChR antibodies <u>or</u> MuSK antibodies (required)
☐ If ordering a subsequent treatment cycle, and patient is new to Paragon, please indicate the start date of the last completed cycle
Other medical necessity:

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance